Supernus Pharmaceuticals (SUPN) Non-Current Deferred Tax Liability (2015 - 2025)

Supernus Pharmaceuticals has reported Non-Current Deferred Tax Liability for 8 years, with the latest figure at $161.5 million in Q4 2025.

• Non-Current Deferred Tax Liability for Q4 2025 came in at $161.5 million, up 17.29% year-over-year; the trailing twelve-month figure through Dec 2025 was $161.5 million (up 17.29% YoY), and the FY2025 annual result was $161.5 million, up 17.29% from the prior year.
• Non-Current Deferred Tax Liability climbed to $161.5 million in Q4 2025, from $981000.0 in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $229.6 million in Q4 2021 and troughed at $981000.0 in Q1 2025.
• A 5-year average of $73.2 million and a median of $47.0 million in 2023 frame the typical range for Non-Current Deferred Tax Liability.
• The widest annual swing landed in 2022, when Non-Current Deferred Tax Liability jumped 97.98%; it then sank 94.97% in 2025.
• A 5-year view of Non-Current Deferred Tax Liability shows it stood at $229.6 million in 2021, then declined by 19.58% to $184.7 million in 2022, then fell by 15.39% to $156.3 million in 2023, then declined by 11.88% to $137.7 million in 2024, then increased by 17.29% to $161.5 million in 2025.
• Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $161.5 million in Q4 2025, $981000.0 in Q1 2025, and $137.7 million in Q4 2024.